KR20240023522A - 감염 후 자가면역성 당뇨병을 치료하는 방법 - Google Patents

감염 후 자가면역성 당뇨병을 치료하는 방법 Download PDF

Info

Publication number
KR20240023522A
KR20240023522A KR1020237043749A KR20237043749A KR20240023522A KR 20240023522 A KR20240023522 A KR 20240023522A KR 1020237043749 A KR1020237043749 A KR 1020237043749A KR 20237043749 A KR20237043749 A KR 20237043749A KR 20240023522 A KR20240023522 A KR 20240023522A
Authority
KR
South Korea
Prior art keywords
day
teplizumab
dose
course
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237043749A
Other languages
English (en)
Korean (ko)
Inventor
프란시스코 레온
Original Assignee
프로벤션 바이오, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프로벤션 바이오, 인코포레이티드 filed Critical 프로벤션 바이오, 인코포레이티드
Publication of KR20240023522A publication Critical patent/KR20240023522A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
KR1020237043749A 2021-05-24 2022-05-24 감염 후 자가면역성 당뇨병을 치료하는 방법 Pending KR20240023522A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163192414P 2021-05-24 2021-05-24
US63/192,414 2021-05-24
PCT/US2022/030780 WO2022251258A1 (en) 2021-05-24 2022-05-24 Methods for treating post infectious autoimmune diabetes
US17/752,650 2022-05-24
US17/752,650 US20220372146A1 (en) 2021-05-24 2022-05-24 Methods for treating post infectious autoimmune diabetes

Publications (1)

Publication Number Publication Date
KR20240023522A true KR20240023522A (ko) 2024-02-22

Family

ID=84104472

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237043749A Pending KR20240023522A (ko) 2021-05-24 2022-05-24 감염 후 자가면역성 당뇨병을 치료하는 방법

Country Status (10)

Country Link
US (1) US20220372146A1 (https=)
EP (1) EP4347021A4 (https=)
JP (1) JP2024521164A (https=)
KR (1) KR20240023522A (https=)
CN (1) CN117794572A (https=)
AU (1) AU2022283272A1 (https=)
CA (1) CA3219473A1 (https=)
IL (1) IL308627A (https=)
MX (1) MX2023013849A (https=)
WO (1) WO2022251258A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法
EP4532552A4 (en) * 2022-05-24 2025-10-22 Provention Bio Inc METHODS AND COMPOSITIONS FOR PREVENTING OR DELAYING TYPE 1 DIABETES
TW202506177A (zh) * 2023-03-30 2025-02-16 美商普泛森生技公司 減少外源性胰島素使用之方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090142338A1 (en) * 2005-03-04 2009-06-04 Curedm, Inc. Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
SG177907A1 (en) * 2006-06-14 2012-02-28 Macrogenics Inc Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
WO2015073833A1 (en) * 2013-11-15 2015-05-21 Pharmacyclics, Inc. Methods for delaying or preventing the onset of type 1 diabetes
WO2020232247A1 (en) * 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
CA3148179A1 (en) * 2019-08-20 2021-02-25 Bruce J. Mccreedy Jr. Lymphodepletion dosing regimens for cellular immunotherapies
IL298999A (en) * 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
JP2024520444A (ja) * 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法
EP4532552A4 (en) * 2022-05-24 2025-10-22 Provention Bio Inc METHODS AND COMPOSITIONS FOR PREVENTING OR DELAYING TYPE 1 DIABETES

Also Published As

Publication number Publication date
CN117794572A (zh) 2024-03-29
EP4347021A4 (en) 2025-04-23
IL308627A (en) 2024-01-01
AU2022283272A1 (en) 2023-12-07
US20220372146A1 (en) 2022-11-24
EP4347021A1 (en) 2024-04-10
WO2022251258A1 (en) 2022-12-01
JP2024521164A (ja) 2024-05-28
MX2023013849A (es) 2023-12-08
CA3219473A1 (en) 2022-12-01

Similar Documents

Publication Publication Date Title
KR20240024098A (ko) 제1형 당뇨병의 치료 방법
US20250304688A1 (en) Methods and Compositions Comprising Anti-CD3 Antibodies and DYRK1A Inhibitors for Treating Diabetes
KR20240023522A (ko) 감염 후 자가면역성 당뇨병을 치료하는 방법
US20260008850A1 (en) Methods for delaying onset of type 1 diabetes
WO2024182767A1 (en) Methods and compositions for treating type 1 diabetes comprising teplizumab and verapamil
Chaves et al. Immunogenicity of hepatitis B vaccine among hemodialysis patients: effect of revaccination of non-responders and duration of protection
CA3110276A1 (en) Treatment of triple negative breast cancer with targeted tgf-b inhibition
JP2026513265A (ja) 外因性インスリン使用を低減するための方法
JP2025517856A (ja) １型糖尿病を予防又は遅延させるための方法及び組成物
KR20260046157A (ko) 1형 당뇨병을 치료하기 위한 방법
CN117940162A (zh) 用于治疗糖尿病的包含抗cd3抗体和dyrk1a抑制剂的方法和组合物
TW202545563A (zh) 用於治療iga腎病(igan)之抗c5抗體的劑量與投予
CN118591558A (zh) 用于预防或推迟第1型糖尿病的方法及组合物
WO2021207667A1 (en) Compositions and methods for treating lung injury or acute respiratory distress syndrome (ards)
HK40053741A (en) Methods and compositions for preventing type 1 diabetes
CN112839707A (zh) 用于预防i型糖尿病的方法和组合物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000